JP2023536653A5 - - Google Patents

Info

Publication number
JP2023536653A5
JP2023536653A5 JP2023507863A JP2023507863A JP2023536653A5 JP 2023536653 A5 JP2023536653 A5 JP 2023536653A5 JP 2023507863 A JP2023507863 A JP 2023507863A JP 2023507863 A JP2023507863 A JP 2023507863A JP 2023536653 A5 JP2023536653 A5 JP 2023536653A5
Authority
JP
Japan
Prior art keywords
binding molecule
molecule according
sdab
viral vector
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023507863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536653A (ja
JP7803927B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044575 external-priority patent/WO2022031869A2/en
Publication of JP2023536653A publication Critical patent/JP2023536653A/ja
Publication of JP2023536653A5 publication Critical patent/JP2023536653A5/ja
Priority to JP2026001871A priority Critical patent/JP2026063000A/ja
Application granted granted Critical
Publication of JP7803927B2 publication Critical patent/JP7803927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507863A 2020-08-05 2021-08-04 Gp130結合分子および使用方法 Active JP7803927B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026001871A JP2026063000A (ja) 2020-08-05 2026-01-08 Gp130結合分子および使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063061562P 2020-08-05 2020-08-05
US63/061,562 2020-08-05
US202063078745P 2020-09-15 2020-09-15
US63/078,745 2020-09-15
US202163135884P 2021-01-11 2021-01-11
US63/135,884 2021-01-11
PCT/US2021/044575 WO2022031869A2 (en) 2020-08-05 2021-08-04 Gp130 binding molecules and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026001871A Division JP2026063000A (ja) 2020-08-05 2026-01-08 Gp130結合分子および使用方法

Publications (3)

Publication Number Publication Date
JP2023536653A JP2023536653A (ja) 2023-08-28
JP2023536653A5 true JP2023536653A5 (https=) 2024-07-26
JP7803927B2 JP7803927B2 (ja) 2026-01-21

Family

ID=92301999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507863A Active JP7803927B2 (ja) 2020-08-05 2021-08-04 Gp130結合分子および使用方法
JP2026001871A Pending JP2026063000A (ja) 2020-08-05 2026-01-08 Gp130結合分子および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026001871A Pending JP2026063000A (ja) 2020-08-05 2026-01-08 Gp130結合分子および使用方法

Country Status (10)

Country Link
US (1) US12448457B2 (https=)
EP (1) EP4192862A4 (https=)
JP (2) JP7803927B2 (https=)
KR (1) KR20230061391A (https=)
CN (1) CN117043188A (https=)
AU (1) AU2021320226A1 (https=)
BR (1) BR112023001723A2 (https=)
CA (1) CA3190459A1 (https=)
MX (1) MX2023001491A (https=)
WO (1) WO2022031869A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284449B (zh) * 2023-02-27 2024-11-19 深圳市先康达生命科学有限公司 增强型TGF-βR嵌合受体及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198919B1 (en) 1983-04-25 2007-04-03 Genentech, Inc. Use of alpha factor sequences in yeast expression systems
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5439829A (en) 1991-01-30 1995-08-08 Eli Lilly And Company Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5320663A (en) 1992-07-02 1994-06-14 E. I. Du Pont De Nemours And Company Method of obtaining lead and organolead from contaminated media using metal accumulating plants
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
MXPA06014067A (es) 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
JP2009543579A (ja) 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのWSX−1/p28
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
AU2012205384B2 (en) 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US20140155581A1 (en) 2011-07-06 2014-06-05 Medimmune, Llc Methods For Making Multimeric Polypeptides
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013059299A1 (en) 2011-10-17 2013-04-25 The Uab Research Foundation Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN115160441A (zh) 2013-09-26 2022-10-11 埃博灵克斯股份有限公司 双特异性纳米抗体
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015175957A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
LT3611192T (lt) 2015-05-13 2025-06-25 Ablynx N.V. T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
CN107400166A (zh) 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
US11377497B2 (en) * 2017-01-23 2022-07-05 Suzhou Alphamab Co., Ltd. PD-L1 binding polypeptide or composite
WO2018182935A1 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Synthekine compositions and methods of use
EP3634465A4 (en) 2017-05-25 2021-01-20 The Broad Institute, Inc. LYMPHOCYTE ANTIGEN CD5 SIMILAR (CD5L) MONOMER, HOMODIMER AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHOD OF USE THEREOF
KR20240141853A (ko) 2017-08-03 2024-09-27 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
SG11202008731XA (en) 2018-06-19 2020-10-29 Nanjing Legend Biotech Co Ltd Engineered cells and uses thereof
WO2020036867A1 (en) 2018-08-13 2020-02-20 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
CN111018985B (zh) 2019-12-06 2021-06-18 南京融捷康生物科技有限公司 针对牛血清白蛋白bsa的单域抗体的应用
MX2023001415A (es) 2020-08-05 2023-04-24 Synthekine Inc Composiciones y métodos relacionados con la unión al receptor de il27.
EP4192490A4 (en) 2020-08-05 2025-01-01 Synthekine, Inc. IL27RA-BINDING MOLECULES AND METHODS OF USE
EP4200339A4 (en) 2020-08-05 2025-04-30 Synthekine, Inc. Compositions and methods related to receptor pairings

Similar Documents

Publication Publication Date Title
JP2023536654A5 (https=)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2023538518A5 (https=)
EP4198055A1 (en) Antibody of il-11 and use thereof
JP2022513420A5 (https=)
JP2020511113A (ja) 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
CN110121509A (zh) 中和抗tl1a单克隆抗体
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
TWI902681B (zh) 抗cd79b抗體、其抗原結合片段及其醫藥用途
JP2022502024A5 (https=)
JP2017507131A5 (https=)
US20250263467A1 (en) Antibody therapies for sars-cov-2 infection
JP6918005B2 (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
CN114805563B (zh) SARS-CoV-2 α、γ、δ和ο突变株骆驼源高亲和力纳米抗体
CN114591434A (zh) 抗Siglec15抗体及其制备方法和用途
WO2025242094A1 (zh) 靶向bdca2的抗体或其抗原结合片段及其应用
CN120712286A (zh) 抗体、抗原结合片段和使用方法
CN121358774A (zh) 与nkg2a结合的抗体或抗原结合片段及其用途
JP2023536653A5 (https=)
TW202308649A (zh) 用於治療卵巢癌之卡鉑與靶向NaPi2b之抗體聚合物-藥物共軛體的組合療法
KR102822827B1 (ko) 칸디다에 대한 항체 및 이의 용도
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
TW201043961A (en) Methods for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
JP2025507761A (ja) 罹患造血幹細胞の枯渇のための組成物および方法